Tium Bio

Happiness of mankind through rare disease therapeutics

Tium Bio was founded in 2016, is headquartered in Seongnam-si, South Korea, lists 51–200 employees, and has 1 recorded funding round.

Headquarters
Seongnam-si
Employees
51–200
Founded
2016
Business Model
B2B
Last Round
Series BJan 2016
Rounds
1

Indexed holds 1 funding round and 2 investors for this company. The full record is or through the API.

About

TiumBio (KOSDAQ: 321550) is a clinical-stage biopharmaceutical company based in Seongnam-si, South Korea focused on discovering and developing innovative small molecule and biologic therapeutics for patients with rare and incurable diseases. Its lead pipeline assets include TU2218, an oral immuno-oncology therapy targeting TGF-beta and VEGFR2 currently in Phase 2 trials, TU2670, an orally active GnRH antagonist for uterine fibroids and assisted reproduction, and TU7710, a bypass-factor therapy for hemophilia patients with inhibitors. TiumBio serves oncology, rare disease, and women's health patient populations globally and operates subsidiaries including Boston-based Initium Therapeutics and CDMO company Protium Science.

Summary

Tium Bio is a Biotech company based in Seongnam-si, South Korea, founded in 2016. It lists 51–200 employees. Its most recent funding was a Series B round in Jan 2016. Investors include IMM Investment and KIP Global Pharma Private Equity Fund.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries B2016 (est.)

Investors

Similar Companies

BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
Avenzo

Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation o...

San Diego, United States1–10Biotech, Oncology
Series BTotal funding$832.0MSep 2025
Bicycle TherapeuticsIPO

Novel bicyclic peptides and drug conjugates for cancer

Cambridge, United States201–500Biotech, Oncology
Private EquityTotal funding$607.0MJan 2024
Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
ParexelAcquired

One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...

Raleigh, United States10001+Biotech
Private EquityTotal funding$5.0BJun 2017
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Tium Bio on Indexed.vc
<a href="https://indexed.vc/companies/tium-bio"><img src="https://indexed.vc/api/badge/company/tium-bio" alt="Tium Bio on Indexed.vc" width="260" height="76" /></a>